This new data indicates that there may be potential for clinicians to maintain their typical lung cancer screening model’s accuracy and also reduce racial and ethnic disparities.
Interstitial lung disease is a serious life-limiting condition which can occur in people with rheumatoid arthritis. How does one monitor this condition? Test your knowledge with this quiz.
The analysis of questionnaire responses in Sweden suggests the socioeconomic factor of low household income had a crucial impact on vision-related quality of life.
An analysis of patient data from a health system in southern California suggests both type 1 and type 2 diabetes rates rose among younger populations during the COVID-19 pandemic, affecting non-Hispanic Black and Hispanic youth most significantly.
Nearly half of patients with IBD in remission experienced abdominal pain, which was associated with sex, fatigue, and depressive symptoms.
A study of more than 500 patients with severe psoriasis provides further insight into the association between severe psoriasis and cardiovascular disease risk, demonstrating coronary microvascular dysfunction was present in 30% of this cohort.
Although intervention increased HCV RNA testing compared to patients in the standard of care group, treatment uptake was unaffected.
A review of Japan post-marketing data support the biosimilar in use for psoriasis, rheumatoid arthritis, Crohn's disease and ulcerative colitis.
Biosimilar infliximab-dyyb proves successful in achieving and maintaining the control of non-infectious uveitis in the study cohort.
This new research concluded that the unclear nature of safety outcomes indicated additional research and enhanced monitoring of patients’ adverse events may be necessary.
Artificial intelligence use is growing across medicine. From imaging to chatbots, ophthalmology is the center of one of these transformations.
Elevated serum endotrophin levels, but not urinary endotrophin levels, predict increased risk of kidney complications and mortality in type 1 diabetes.
More patients who retransitioned to originator infliximab after switching to a biosimilar discontinued infliximab than patients who remained on the biosimilar.
The FDA's announcement requesting further study represents a step back in the process of 'neffy' becoming the first needle-free nasal spray epinephrine alternative.
The greatest level of treatment discontinuation was seen among patients aged 18-24 years, highlighting an increased risk of early disease relapse.
This segment of Dr. Kim’s interview featured a discussion on the potential advantages and disadvantages of the new ARS-1 epinephrine nasal spray being considered by the FDA.
For DME eyes that did not sufficiently respond to prior treatment, the intravitreal implant was associated with improvements in both visual and anatomic outcomes.
The company shared anticipation that their BLA decision for bimekizumab to treat adults with plaque psoriasis will not come before the end of this month.
Most patients continued treatment with the adalimumab biosimilar over 2 years, with a treatment retention rate of 73.1%.
Announced by Iveric Bio, topline results from the phase 3 GATHER2 clinical trial indicate monthly avacincaptad pegol significantly slowed GA growth compared to sham at 24 months.
In a new interview with the HCPLive editorial team, Edwin H. Kim, MD, spoke about the new ARS-1 (Neffy) intranasal epinephrine spray for patients having Type 1 allergic reactions as well as the FDA's upcoming decision on the treatment.
Increased physical activity and diet quality were associated with a lower risk of all-cause and cardiovascular disease-related mortality among patients with NAFLD.
The potassium-competitive acid blocker drug class is coming to US digestive disease management. How does it fare to standard antacids and PPIs for GERD?
In their latest recommendation statement, the USPSTF recommends blood pressure screening for all pregnant individuals to detect hypertensive disorders.
These new results from the pivotal INTEGUMENT-PED trial met both of the investigators' primary and secondary endpoints.
The UT Health infectious disease specialist reviews new vaccine and treatment options, as well as the threat of an RSV-flu-COVID "triple-epidemic" in this winter season.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a breakdown of the latest news in diabetes management, including FDA clearance of a new insulin pump and a major acquisition within the diabetes world.
Findings showed colonization with toxigenic C. difficile was associated with a greater risk of CDI during hospitalization than cross-transmission.
In this interview segment, Jayme Heim, MRS, explored promising treatments on the horizon, hidradenitis suppurativa, and future research on teledermatology and artificial intelligence.
Patients were treated with fewer anti-VEGF injections in 2020 compared to the previous year, but these changes did not significantly impact BCVA outcomes.
